These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26780109)

  • 1. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.
    Stachel D; Stevens-Ayers T; Boeckh M
    J Clin Virol; 2016 Feb; 75():53-9. PubMed ID: 26780109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
    Winston DJ; Saliba F; Blumberg E; Abouljoud M; Garcia-Diaz JB; Goss JA; Clough L; Avery R; Limaye AP; Ericzon BG; Navasa M; Troisi RI; Chen H; Villano SA; Uknis ME;
    Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
    Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
    Bright PD; Gompels M; Donati M; Johnston S
    J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient.
    Benz C; Holz G; Michel D; Awerkiew S; Dries V; Stippel D; Goeser T; Busch DH
    Transplantation; 2003 Mar; 75(5):724-7. PubMed ID: 12640316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
    Winston DJ; Young JA; Pullarkat V; Papanicolaou GA; Vij R; Vance E; Alangaden GJ; Chemaly RF; Petersen F; Chao N; Klein J; Sprague K; Villano SA; Boeckh M
    Blood; 2008 Jun; 111(11):5403-10. PubMed ID: 18285548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
    Chou S; Marousek GI
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
    Chou S; Wu J; Song K; Bo T
    Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
    Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
    Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.
    Sester M; Sester U; Gärtner BC; Girndt M; Meyerhans A; Köhler H
    J Am Soc Nephrol; 2002 Oct; 13(10):2577-84. PubMed ID: 12239248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors.
    Hoegh-Petersen M; Roa L; Liu Y; Zhou F; Ugarte-Torres A; Louie P; Fonseca K; Khan F; Russell JA; Storek J
    Cytotherapy; 2012 Feb; 14(2):194-204. PubMed ID: 22149135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
    Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
    Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature.
    Egli A; Bergamin O; Müllhaupt B; Seebach JD; Mueller NJ; Hirsch HH
    Transpl Infect Dis; 2008 Feb; 10(1):27-43. PubMed ID: 18086275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.